Genentech VP-Business Development Joseph McCracken: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Product development and deal flow at Genentech have a “biological focus” rather than a therapeutic area focus, McCracken says.
You may also be interested in...
Genentech Adds Patient Assistance Program Along With Avastin Lung Cancer Indication
Program similar to Amgen’s for Vectibix.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.